Bibliografía

  • 1. Resumen de las Características del Producto de alli. GlaxoSmithKline Consumer Healthcare.
  • 2. ABC of Obesity. Eds. Sattar N and Lean M. 2007, Blackwell Publishing, Massachusetts, USA. (Disponible en FT)
  • 3. World Health Organisation. Quantifying selected major risks to health. Chapter 4 in: the World Health Report 2002. http://www.who.int/whr/2002/en/whr02_ch4.pdf
  • 4. Obesity - Clinical Knowledge Summary guidance. http://cks.library.nhs.uk/obesity
  • 5. Hamman RF, Wing RR, Edelstein SL et al. Effects of weight loss. Diabetes Care 2006; 29: 2102 - 2107.
    http://care.diabetesjournals.org/cgi/content/full/29/9/2102
  • 6. Neter J et al. Influence of weight reduction on blood pressure; a meta analysis of randomized controlled trials. Hypertension 2003; 42: 878 - 884.
    http://hyper.ahajournals.org/cgi/reprint/42/5/878
  • 7. Lean M. Management of obesity and overweight. Medicine 2006; 34(12): 515 - 520 (Ref 222).
    (Copia impresa disponible en FT)
  • 8. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16(6): 397 - 415.
    (Copia impresa disponible en FT)
  • 9. Blackburn G. Effect of Degree of Weight Loss on Health Benefits. Obes Res 1995; 3(Suppl 2): 211s - 216s.
    (Copia impresa disponible en FT)
  • 10. Van Gaal L et al. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obesity 1997; 21(Suppl 1):S5 - S9.
    (Copia impresa disponible en FT)
  • 11. Ross R. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. Ann Intern Med 2000;133:92 - 103. http://www.annals.org/cgi/reprint/133/2/92.pdf
  • 12. European Conference on Counteracting Obesity: 10 things you need to know about obesity. World Health Organisation; Istanbul, Turkey: 15 - 17 November 2006. http://www.euro.who.int/Document/NUT/ObesityConf_10things_Eng.pdf
  • 13. Mintel report. Dieting, Market Intelligence. February 2008. (Disponible en FT)
  • 14. International Association for the Study of Obesity. Overweight and obesity in the EU27. July 2008. http://www.iotf.org/database/documents/v2PDFforwebsiteEU27.pdf
  • 15. BMI Classification, WHO Global database on Body Mass Index. Last update 14.07.2008. http://www.who.int/bmi/index.jsp?introPage=intro_3.html
  • 16. Anderson J, Konz E. Obesity and Disease Management: Effects of Weight Loss on Comorbid Conditions. Obes Res. 2001; 9(Suppl 4): 326S - 334S. http://www.nature.com/oby/journal/v9/n11s/pdf/oby2001138a.pdf
  • 17. The challenge of obesity in the WHO European Region and the strategies for response. World Health Organisation; Copenhagen, Denmark: 2007.
    http://www.euro.who.int/document/E90711.pdf
  • 18. Haslam D. Obesity - time to wake up. BMJ 2006; 333(7569): 640 - 642. http://www.bmj.com/cgi/reprint/333/7569/640
  • 19. Haslam D. Managing the overweight/obese patient. Practice Nurse 2008; 35(6): 26 - 29. (Copia impresa disponible en FT)
  • 20. Hill AJ. Psychological aspects of obesity. Psychiatry 2005; 4: 26 - 30. (Copia impresa disponible en FT)
  • 21. i-alli research. Gemini Qualitative Debrief, November 2007. (GSK, datos de archivo)
  • 22. Anderson J et al. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16-week double-blind, placebo-controlled trial. Ann Pharmacother 2006; 40: 1717 - 23. Low-Dose Orlistat Effects on Body Weight of Mildly to ModeratelyOverweight Individuals: A 16 Week, Double-Blind, Placebo-Controlled Trial -- Anderson et al. 40 (10): 1717 -- The Annals of Pharmacotherapy
  • 23. Schwartz S et al. Compliance, behaviour change, and weight loss with orlistat in an over-the-counter setting. Obesity 2008; 16(3): 623 - 29.
    http://www.nature.com/oby/journal/v16/n3/pdf/oby200796a.pdf
  • 24. Zhi J et al. Retrospective population-based analysis of the does-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994; 56:82 - 85.
  • 25. Anderson J. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother 2007; 8(11): 1733 - 42.
    http://www.expertopin.com/doi/pdf/10.1517/14656566.8.11.1733
  • 26. Zhi J et al. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999; 39(1): 41-46.
    Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients -- Zhi et al. 39 (1): 41 -- The Journal of Clinical Pharmacology
  • 27. Jacob S, Togerson J. Orlistat Treatment Beneficial in Both Primary Care and Tertiary Settings. Obesity Reviews 2005; 6(s1):166. Wiley InterScience :: Journal :: Article PDF
  • 28. Rossner S et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8(1): 49 - 61. http://www.nature.com/oby/journal/v8/n1/pdf/oby20008a.pdf
  • 29. Hauptman J et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160 - 167.
    Orlistat in the long-term Treatment of Obesity in Primary Care Settings - Hauptman
    et al. 9 (2): 160 -- Archives of Family Medicine
  • 30. Resumen de las Características del Producto de Xenical® Roche Products Ltd.
  • 31. Food-based guidelines in the WHO European region. World Health Organisation; Copenhagen, Denmark: 2003.
    http://www.euro.who.int/Document/E79832.pdf
  • 32. Fox M et al. The pathophysiology of faecal spotting in obese subjects during treatment with orlistat. Aliment Pharmacol Ther 2004; 19: 311 - 21. Wiley InterScience :: Journal :: Article PDF
  • 33. Tsigos C et al. Eur J Obesity - Obesity facts 2008.
    http://www.eco2008.org/documents/10EASOEuropeanobesitymanagementguidelines.pdf
  • 34. GSK datos de archivo (estudios combinados BM14149 y NM 14161).
  • 35. Dev V et al. Cumulative data on OTC orlistat show efficacy, not treatment effects, correlate with patient satisfaction. Obesity 2007; 15(9): A86-274-P. (Resumen)
  • 36. Bansal V et al. Low dose orlistat provides significant benefit. Obesity Reviews 2006; 7(Suppl 2): 332. (Resumen)
  • 37. Chanoine JP. 2008. Data presented at the European Congress on Obesity, Geneva, May 2008 during the symposium "Obesity - A Short History in Time" (Roche).
  • 38. European Charter on Counteracting Obesity. World Health Organisation; Istanbul, Turkey: 16 November, 2006.
    http://www.euro.who.int/Document/E89567.pdf
  • 39. Folleto de información para los pacientes de alli. GlaxoSmithKline Consumer Healthcare.

 

Ver más detalles sobre alli

Registrase